TY - JOUR
AU - Li, Qinchuan
AB - INTRODUCTIONLung cancer has become a global concern because of its high mortality and morbidity. Approximately 2.2 million new cases and 1.8 million deaths were reported in 2020.1 Chinese national statistics showed that 631,000 individuals died of lung cancer in 2015.2 The wide usage of low‐dose computed tomography for screening has led to an increase in the number of cases with small nodules or ground‐glass opacity and lung adenocarcinoma has become the most common subtype.3 The discovery of oncogenic driver mutations/translocations has dramatically improved the overall survival of patients, especially in the Asian population, who have benefitted from targeted therapy. However, drug resistance is still an inevitable problem. Immunotherapy targeting checkpoint inhibitors has achieved a substantial overall survival improvement and shifted the paradigm of treatment in the advanced stages of lung adenocarcinoma. However, immune‐related adverse events, including immune‐related myocarditis, pneumonitis, colitis, hepatitis and endocrine dysfunction, have become global issues.4Histones are basic nuclear proteins that are responsible for the nucleosome structure of the chromosomal fiber in eukaryotes.5 Histones are classified into five types: H1, H2A, H2B, H3 and H4. The N‐ and C‐terminal tails of these histone proteins can be post‐translationally modified, such as with acetylation, methylation, phosphorylation, SUMOylation and ubiquitination. 
TI - Inhibition of HIST1H2AB suppresses the proliferation of lung adenocarcinoma
JF - Journal of Gene Medicine
DO - 10.1002/jgm.3469
DA - 2023-05-01
UR - https://www.deepdyve.com/lp/wiley/inhibition-of-hist1h2ab-suppresses-the-proliferation-of-lung-k9D6BdZ0kF
VL - 25
IS - 5
DP - DeepDyve
ER -